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 DIGESTIVE DISEASES 
 
Early and Late Crohn’s Disease Are Distinct Entities 
 








Phenotypically, the transition from early to late Crohn’s disease 
is characterized by the occurrence of complications including 
strictures, intra-abdominal fistulas and perianal fistulas, 
all of them leading to various types of surgeries and 
currently non-reversible tissue damage. It must, however, be 
kept in mind that this transition is not at all a uniform and 
linear process. According to these simple phenotypic criteria, 
Crohn’s disease can already be a late disease at diagnosis 
while in other patients, it can still be an early disease after 
20 years of evolution. This simply highlights the relativity of 
time in this field, actually reflecting the nature, location and 
severity of the inflammatory process. The risk over time of 
the development of these complications has been described, 
first in cohort studies and then in population-based studies. 
Globally, at diagnosis, between 19 and 38% only of Crohn’s 
disease patients have complicated Crohn’s disease. After 
10 years, between 56 and 65% of patients have developed 
either stricturing or penetrating complications. After 20 
years, these numbers are between 61 and 88%. In parallel to 
these structural changes, changes in the immunobiology of 
the disease also seem to occur; the latter seem to happen 
quicker with major modification already within 2 years of the 
diagnosis. Beside these general figures, important questions 
remain pending. First, the real timing of these changes is still 
unclear. Second, the precise role of genetics and environment 
in the development of these changes remains to be 
clarified. Third, the correlation between changes in immunobiology 





In Crohn’s disease, the age of the disease does not necessarily 
correlate with time. Indeed, a late disease, as opposed 
to an early disease, is characterized by the presence 
of either stricturing or penetrating complications. The 
penetrating complication may develop in the abdomen, 
arising from intestinal loops, or in the perianal region. 
These complications usually lead to surgical resections, 
but may develop at different speeds, sometimes already 
being present at diagnosis in a significant proportion of 
patients. Therefore, in Crohn’s disease, an ‘early’ disease 
can already be a ‘late’ disease [1, 2] . Changes in the immunobiology 
of the disease may parallel these structural 
changes of the intestine, although less data is available on 
this subject [3, 4] . The relevance of this transition from 
early to late disease is linked to the fact that it seems to 
determine a change in response to treatment [5] , and beyond 
this, even a change in the realistic objectives of a 
treatment strategy, as has been suggested in rheumatoid 
arthritis [6] and which could be extrapolated to Crohn’s 
disease. In early disease, a deep remission and no tissue 
damage can be reached, while in late disease only an 
improvement of symptoms and the healing of lesions is 
possible. The aim of this article is to report on the epidemiology 
of this transition from early to late disease. We 
will describe the number and proportion of patients in 
the literature who develop features of late Crohn’s disease 
over time, and we will highlight the remaining questions 
important for a better understanding of the natural history 
of Crohn’s disease. 
 
Cumulative Risk of Complications and Surgery 
 
The development of the stricturing and penetrating 
complications of Crohn’s disease was first described in 
cohort studies performed in referral centres. In a first 
study from Liège, according to the Vienna classification, 
proportions of patients with pure stricturing and penetrating 
disease (including perianal disease) were 10.8 and 
15.5% at diagnosis, 32.2 and 37.2% after 10 years and 32 
and 48.8%, after 20 years, respectively [1] . In a simultaneous 
study on a larger cohort from Paris, similar proportions 
were found, although a substantially greater 
proportion developed penetrating disease, with 18% with 
stricturing disease and 70% with penetrating disease 20 
years after the diagnosis, respectively [2] . More recently, 
a first population-based study reported on the long-term 
follow-up and development of complications in Crohn’s 
disease. In this study, the Montreal classification was 
used, excluding perianal disease from the penetrating 
complication. A slightly lower proportion of patients was 
shown to develop structuring and penetrating complications 
with 4.6 and 14% at stricturing diagnosis, 15.2 and 27.5% after 
10 years and 21.6 and 37.1% after 20 years, respectively [7] . 
When adding perianal disease to stricturing and penetrating 
disease, the overall proportion of patients with 
such complications reached 60.6% after 20 years. 
When analyzing the occurrence of perianal complications 
independently, various prevalences were reported, 
ranging from 10 to 37% depending on the definition 
of perianal disease and the time of follow-up [8–10] . In 
a population-based study from Olmsted County, Minn., 
the cumulative incidence of perianal disease was below 
10% at diagnosis and had reached 26% after 20 years [10] . 
The stricturing and penetrating complications of 
Crohn’s disease are often indications for surgical resection, 
which is also a marker of late Crohn’s disease. In 
Norway, Denmark and a European collaborative study, 
the rate of surgical resection after 10 years was 38, 55 and 
40%, respectively [11–13] . At 30 years, it reached 64% in a 
population-based study from Olmsted County [14] and 
was above 80% in the National Cooperative Crohn’s Disease 
study from the USA [15] . 
 
Tissue Damage and Disability as Markers of the Age 
of the Disease 
 
As highlighted in the previous paragraph, the most 
relevant impact of time on Crohn’s disease may be the 
development of complications that potentially lead to 
surgery. Overall, these could be grouped under the term 
‘tissue damage’. Indeed, it has recently been proposed 
that the nonreversible cumulative tissue damage is the 
most relevant outcome that should be measured to assess 
the real impact of different treatment strategies. A 
late disease would then be characterized by the accumulation 
of this tissue damage, and the epidemiology of the 
standardized measure of it could help us to better define 
the age of the disease. Hence, an international collaborative 
research group is currently aiming at validating 
a standardized score of tissue damage [16] . In parallel to 
tissue damage, the patient may also develop different 
degrees of disability. Such a disability score may thus 
also help to differentiate early versus late disease. With 
the collaboration of the World Health Organization, a 
disability score has recently been built up in Crohn’s disease [17] . 
 
Changes in the Immunobiology of the Disease 
 
Beside these structural intestinal changes and their 
consequences, relevant changes in the immunobiology of 
Crohn’s disease may also reflect disease evolution and 
represent good markers of the disease’s age. In particular, 
a change in T cell polarization and cytokine production 
has been consistently described [3, 4] . Higher production 
of interleukin (IL)-12 seems to reflect earlier disease, 
while later a Th17 profile seems to appear. This change 
may be much more rapid than the manifestation of 
structural damage as it occurs mainly within 2 years of 
the diagnosis. However, so far, no standardized definition 
of late disease according to these criteria has been 
proposed, and data on the correlation between these 
immunobiological changes and the structural damage 
are lacking. 
 
Impact of the Disease’s Age on Response to 
Treatment 
 
One of the most relevant consequences of disease duration 
is an apparent decrease in the ability to respond to 
different drugs including antitumor necrosis factor (anti- 
TNF) treatment. Different reasons have been proposed to 
explain this diminished response, including tissue damage 
and particularly the stricture formation, but also a 
change in the immune status of the patients. From this 
point of view, the transition from early to late Crohn’s 
disease may be more rapid than for tissue damage or disability 
and may parallel more the immunobiological 
changes; a significant decrease in the ability to respond 
to anti-TNF has been described after already 1 year of 
duration of the disease and even more strikingly after 




As highlighted by the previous paragraphs, the amount 
of data on the epidemiology of transition from early to 
late Crohn’s disease and indeed, on the definition itself of 
these entities, is scarce. There are currently more questions 
than answers in this field. In the following paragraphs, 
we aim to describe the most relevant question and 
elements of response. 
 
What Is the Real Natural History of These 
Complications? 
There is no study that precisely and prospectively describes 
the occurrence of tissue damage including fibrosis, 
strictures or fistulae. These complications are usually diagnosed 
when they become symptomatic, but the time that 
has elapsed between active inflammation and the development 
of these lesions is not known. From experimental 
models or from other human diseases, including ischemic 
colitis, we know that it may be very rapid and that a tight 
stricture does not necessarily reflect a long-standing inflammatory 
process [18] . It is probable that this process 
may very much vary from patient to patient depending on 
their genetic background, the intensity and depth of the 
inflammation and maybe on environmental factors including 
the composition of the intestinal flora [19] . 
 
What Is the Correlation between Structural Changes 
in the Intestine and Changes in the Immunobiology of 
the Disease? 
As stated earlier in this text, we currently do not know 
if the immunological changes that have been described 
between early and late Crohn’s disease evolve in parallel 
or may precede and influence the remodeling of the intestine, 
leading, in turn, to tissue damage and complications. 
 
What Is the Role of Genetics and Environment in the 
Development of Complications? 
Genetics and environment most probably play an important 
role in the development of Crohn’s disease complications 
and intestinal tissue aging. Besides the factors 
determining the intensity, location and depth of the inflammation 
itself, specific factors may influence the inclination 
to develop fibrotic and/or penetrating lesions. 
However, very few studies have adequately addressed this 
very important question. In a large multivariate analysis 
of a cohort of Belgian patients, the environmental, clinical, 
serologic and genetic factors associated with the development 
of stricturing or penetrating lesions in Crohn’s 
disease were examined. A variant in a gene encoding for 
a hypothetical protein in the vicinity of the IL12B gene in 
combination with ileal location of the disease was associated 
with stricturing disease, while male gender together 
with a single-nucleotide polymorphism in a gene desert 
of 5p13.1 was associated with internal penetrating disease [20] . 
In an experimental model, the composition of the 
flora also influenced the development of fibrosis [19] . 
The role of genetics and environment regarding other 
features of the transition from early to late disease, such 
as changes in immunobiology, microbiology or the ability 
to respond to treatments, has not been studied. 
 
Can Early and Late Lesions Really Coexist in Crohn’s 
Disease Patients? 
Clinical experience shows that early and late lesions 
may indeed coexist in Crohn’s disease. A patient may harbor 
at the same time an old fibrotic stricture, which has 
been present for several years (and apparently no longer 
developing) and more recent lesions not associated with 
deep-tissue remodeling but rather florid inflammation. 
However, these florid inflammatory lesions in a patient 
with long-standing disease may be characterized by a 
‘late’ immunological profile. Postoperative recurrence 
is another concept-challenging situation: should this be 
considered as early disease again while the disease has 
already had complications? The cytokine profile of the 
mucosa in early recurrent Crohn’s disease is clearly different 
from that of the established lesions [21] , but the 
increase in IL-4 production detected in such postoperative 
lesions has also been described in late lesions in another 




The transition from early to late disease is characterized 
by the occurrence of tissue damage leading to disease 
complications and disability. It appears in parallel with a 
change in the immunobiology of the disease and leads to 
a change in the ability to respond to medical treatment, 
anti-TNF in particular. This transition occurs at different 
speeds in different patients, but in the most aggressive 
disease profiles, it is quick and intense, occurring within 
1 year of disease onset. The changes in immunobiology 
and partly in response to treatment seem to precede tissue 
damage in the intestine. Much is still to be done to 
better understand the factors involved in these changes 
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